Business
SK bioscience Joins Korea's National Initiative to Develop Avian Influenza Vaccine Amid Rising Pandemic Threats
SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that it has been selected for the Korea Disease Control and Prevention Agency (KDCA)'s Priority Infectious Disease Pandemic Preparedness Rapid R&D Support Program.
About this update from Sk Bioscience Co.,ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"Company aims to develop a bird flu vaccine with rapid mass production and variant responsiveness.","length":97,"tagName":"p"}]},{"val":[{"type":"text","content":"SK bioscience and KDCA join forces to build a national pandemic preparedness and response system for potential next-pandemic avian influenza.","length":141,"tagName":"p"}]},{"val":[{"type":"text","content":""We will promote global public health and grow as a global leader, building on our COVID-19 response experience."","length":123,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":361,"olType":false},{"type":"text","content":"SEONGNAM, South Korea, May 6, 2025 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that it has been selected for the Korea Disease Control and Prevention Agency (KDCA)'s Priority Infectious Disease Pandemic Preparedness Rapid R&D Support Program.","length":367,"tagName":"p"},{"type":"image","alt":"Researchers at SK bioscience are analyzing the vaccine candidate.","displaySize":"","headline":null,"caption":"Researchers at SK bioscience are analyzing the vaccine candidate.","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":267,"url":"https://media.zenfs.com/en/prnewswire.com/89821b0ab9a4e5a87c1fe9486fbbfc47"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1JcH9Y.bEqGvMgzecRVlxg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ3MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/89821b0ab9a4e5a87c1fe9486fbbfc47","width":400,"height":267}},"href":"https://mma.prnewswire.com/media/2680245/Researchers_at_SK_bioscience_are_analyzing_the_vaccine_candidate.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"This government-led initiative aims to develop vaccines against avian influenza – identified as a high-risk candidate for the next pandemic. SK bioscience was chosen for its proven technological capabilities as the only domestic company to have commercialized cell-culture-based vaccines for both influenza and COVID-19.","length":320,"tagName":"p"},{"type":"text","content":"Under the program, SK bioscience and KDCA will co-invest approximately KRW 5.25 billion (USD 3.7 million) in early-stage development. The company will initiate deve...